Health Budget Distress

The National Institutes of Health has released a fact sheet on its budget pain following the sequester.

Written byKate Yandell
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, 401(K) 2013The sequester put into effect on March 1 requires the National Institutes of Health (NIH) to cut spending for 2013 across the board by 5 percent. The agency released documents detailing the planned cuts last month (May 8). Earlier this week (June 3), it released a fact sheet spelling out further details of the sequester’s impacts, including the admission of 750 fewer new patients to the NIH Clinical Center in Bethesda, Maryland, than the hospital admitted in 2012.

The agency will eliminate 703 new grants, and an average of 4.7 percent will be cut from ongoing “noncompeting” grant budgets, but the agency says it will not reduce the duration of grants. Furthermore, the agency’s intramural research program, which is struggling to absorb all of its cuts in the remaining months of the fiscal year, which ends in September, after spending as though it was going to be operating at its full budget until the sequester became official in March. Cuts will not include layoffs or furloughs, but rather the agency will adjust hiring and reduce administrative services contracts.

The fact sheet cites a “delay in medical progress,” such as developing targeted cancer drugs or a universal flu vaccine, as a major impact of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies